key: cord-0717736-dsmgj7wc authors: Ratti, M.; Grizzi, G.; Bonomi, M.; Marchi, R.; Negri, F.; Perrucci, B.; Giganti, M. O.; Panni, S.; Donati, G.; Donini, M.; Foroni, C.; Gobbi, A.; Barbin, F.; Gerevini, F.; Curti, A.; Ferrari, B.; Saleri, J.; Passalacqua, R. title: "DOMONCOVID PROJECT": A homecare model for cancer patients during COVID-19 date: 2020-09-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2020.08.1737 sha: 87628dd7d6d2eab3b4507b48dc62fd3f1f9a903f doc_id: 717736 cord_uid: dsmgj7wc nan Background: The province of Cremona had one of the highest incidence of . The pandemic determined a significant shrinkage of healthcare resources with difficulty for many patients (pts) to be assisted in the hospital, especially for the risk of being infected. We created a homecare project for cancer pts with the aim of reducing hospitalizations, accesses to the oncology ward and emergency room. Methods: The team was composed by oncologists and nurses from the Oncology Unit of Cremona Hospital, supported by a secretary with a dedicated phone number. The assistance was provided from Mon to Sat, 9 AM-5 PM. Cancer pts were eligible if presenting confirmed diagnosis or suggestive symptoms for COV-19. A telephonic triage was performed. Cancer pts and their cohabitants were tested with at least 2 nasopharyngeal swabs (NPS). Blood test, medical examinations and vital parameters were performed. We advised screened individuals to follow the quarantine procedures, providing them with an information leaflet. We administered oral/infusional treatments, including antiviral drugs. Results: From March 23rd to April 30th 2020, 71 cancer pts were assisted at home, with a total of 191 visits. Of the 71 pts tested with NPS, 26 resulted COV-19 positive . 19 of COV-19+ pts had mild symptoms; 7 pts with stable vital parameters and initial pneumonia were successfully treated at home with hydroxychloroquine, antivirals and NSAIDs. 7 pts with severe symptoms were promptly hospitalized. 4 of them died, 2 due to the infection, 2 to progression disease. 52 cohabitants were screened, 28 lived with a COV-19+ cancer patient; in this subgroup, 16 resulted COV-19+.15 of them were asymptomatic. Conclusions: This project demonstrated the feasibility of an innovative model based on homecare assistance for COV-19+ cancer pts with mild symptoms. This strategy, limiting the number of hospital accesses for COV-19+ pts, might be useful to contain the spread of the infection. Further studies are needed to test this strategy in COV-19 negative cancer pts. Moreover, our experience indicates a high probability of identifying asymptomatic positive individuals. NPS screening for asymptomatic subjects is not routinely performed. There is a urgent need to extend the procedure to this population. Legal entity responsible for the study: The authors. Within 3 months before COVID-19 diagnosis, 69% of pts received a systemic anticancer treatment (chemotherapy, targeted or immune therapy) and 22% a local therapy (surgery, radiotherapy or local destruction). Diagnosis of COVID-19 was confirmed by RT-PCR, CT-scan or both in 91% or serology in 1.4%. COVID was treated in the same oncological center in 78%. During the follow-up period (mean 14 days), 208 (25%) pts died, including 173 (21%) COVID-19 related deaths. Conclusions: This first nationwide study of cancer pts with COVID-19 from France reports a high mortality rate. Updated and detailed data on anti-cancer treatments, risk factors of severe and fatal COVID-19 and impact of COVID-19 on cancer management will be presented. Legal entity responsible for the study: Fédération Francophone de Cancérologie Digestive. Funding: Has not received any funding. Disclosure: A. Lièvre: Honoraria (self), Advisory/Consultancy: AAA; Amgen, Pierre Fabre; Sandoz; Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Bayer; Novartis Honoraria (self): Celgene; HalioDx; Lilly Honoraria (self), Travel/Accommodation/Expenses: BMS; Roche Research grant/Funding (self): Incyte Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Merck; Servier; Research grant/Funding (self): Integragen Honoraria (self): Servier; Advisory/Consultancy: Mylan; Merck Serono; Amgen; Travel/Accommodation/Expenses: Merck; Sanofi Ray-Coquard: Honoraria (self), Advisory/Consultancy: Abbvie; Agenus; Advaxis Advisory/Consultancy, Research grant/Funding (self) Advisory/ Consultancy: PharmaMar; Genmab; Pfizer; Deciphera; Mersena; Amgen; Tesaro; Clovis Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/ Funding (self) Advisory/Consultancy, Travel/Accommodation/Expenses: GSK; Non-remunerated activity/ies: GINECO; ENGOT; GCIG; European community; ESMO Italian Health Authority; Belgium Health Authority. J. Thariat: Honoraria (self): BMS; Honoraria (institution), Travel/Accommodation/Expenses, Full/Part-time employment: Centre François Baclesse; Leadership role: President of the French Head and Neck Intergroup, GORTEC secretary Research grant/Funding (institution): Nanobiotix. G. Ahle: Travel/Accommodation/Expenses: Abbvie Mathieu: Honoraria (self), Research grant/Funding (self Honoraria (self): AstraZeneca; Ferring Debieuvre: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Roche; Novartis Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Boerhinger-Ingelheim; Research grant/Funding (institution): Chiesi; Sandoz; Takeda; GSK; Research grant/ Funding (self): Lilly. A. Canellas: Honoraria (self) Honoraria (self), Travel/Accommodation/Expenses: AstraZeneca Travel/Accommodation/Expenses: Oxyvie Advisory/Consultancy: Clovis; Novartis; Roche Advisory/Consultancy: Sandoz; Advisory/ Consultancy: Roche; Eisai; Pfizer; Novartis; Speaker Bureau/Expert testimony: Exact Sciences; Travel/ Accommodation/Expenses: Lilly. P. Gorphe: Honoraria (self): Intuitive Surgical; Non-remunerated activity/ies: Chair, scientific board, French Head and Neck Intergroup; Research grant/Funding (institution): MSD. A. IDBAIH Ahmed: Research grant/Funding (institution): Transgene; Sanofi Travel/Accommodation/Expenses: Carthera Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS Honoraria (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution) Honoraria (institution): Takeda Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Merck KgaA; Bayer; AstraZeneca; Grunenthal Speaker Bureau/Expert testimony Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Servier. All other authors have declared no conflicts of interest